niftify.in

Business Standard

Hero Moto, Cipla, NTPC: Stock picks by Chandan Taparia for today, Sept 18

Stocks to buy today: The stock of Hero MotoCorp has given a range breakout on daily scale with noticeable volumes

The Economic Times

Cipla Stocks Live Updates: Cipla Closes at Rs 1659.70 with Volume Below Weekly Average

undefined

Mint

Top Gainers and Losers today on 5 September, 2024: Titan Company, LTI Mindtree, Cipla, Reliance Industries among most active stocks; Check full list here

Top Gainers and Losers Today : The Sensex lost 151.48 points, or -0.18, to settle at 82352.64, while the Nifty lost 53.6 points, or -0.21, to close at 25198.7.

The Economic Times

As M&A scene hots up, India Inc strengthens in-house legal teams

Large Indian conglomerates are strengthening their in-house legal teams with M&A specialists due to a surge in local and cross-border deals. Companies like Reliance Industries, Cipla, and Aditya Birla Group are hiring experienced lawyers to reduce reliance on external counsel and enhance transaction efficiency.

Business Line

Change at Cipla, as MK Hamied resigns and son Kamil re-enters the drugmaker

The developments involving Cipla’s promoter family come even as reports suggested, as recently as last year, that members of the promoter family were looking to sell their stake

CNBC TV18

Abbott India, Cipla, Biocon may get some relief from the GST Council: Exclusive

Sources further said that the GST council nominated fitment committee is likely to reduce GST on cancer drugs like Trastuzumab Deruxtecan, Osimertinib, Durvalumab to 5% from the current levels of 12%.

Mint

Stocks to Watch: AU Small Finance Bank, GIC, Zee, Cipla, SpiceJet, KIMS, and more

Here’s a quick look at stocks likely to be in focus in today's trade.

Business Line

Stocks that will see action today: September 4, 2024

Buzzing stocks: Raymond, IEX, GIC-RE, Utkarsha SFB, AU SFB, Rane Holdings, Finolex Cables, Cipla, Godrej Phillips, Zee Entertainment, NHPC, GSK Pharma

Mint

Cipla's MK Hamied steps down after 47 years of service from company citing 'age and health' reasons

Cipla Ltd., a leading pharmaceutical company, announced the retirement of its Vice Chairman and Non-Executive Director, MK Hamied, after a tenure spanning 47 years.

Hindustan Times

Cipla's vice-chairman MK Hamied resigns citing age, his son Kamil to join board

Cipla's MK Hamied resigned due to age and health. Kamil Hamied is appointed as Non-Executive Director starting November 1, 2024.

Business Standard

MK Hamied steps down as Cipla's Vice Chairman on account of age, health

Drug major Cipla on Tuesday said MK Hamied has resigned as Vice Chairman with effect from October 29 due to age and health. "It is with a heavy heart that I write to formally announce my resignation from the position of Vice Chairman and Non-Executive Director of the company," he said in a letter to the board of directors. The company said the board has also approved the appointment of Kamil Hamied as Non-Executive Director, with effect November 1, 2024. "I am pleased to see that Kamil Hamied will be joining the Board as a Non-Executive Director to maintain continuity while representing the promoter family," MK Hamied said in the letter.

The Economic Times

Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the board

Cipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamied will join as a non-executive director from November 1, 2024. Cipla also appointed Adil Zainulbhai and Abhijit Joshi as additional directors starting September 3, 2024.

CNBC TV18

MK Hamied resigns as Cipla vice chairman; Kamil Hamied to join as non-executive director

MK Hamied has resigned as Vice Chairman of Cipla, effective 29th October 2024, citing age and health reasons. Kamil Hamied will join the Board as a Non-Executive Director from 1st November 2024, ensuring continuity in leadership.

The Economic Times

Cipla's MK Hamied resigns from the company due to health reasons

Cipla's Vice Chairman and Non-Executive Director, Mr. M K Hamied, has resigned from his position due to age and health reasons. His resignation will be effective from the close of business hours on October 29, 2024. In a letter to employees, Hamied expressed pride in his tenure and confidence in Cipla's future success.

Business Line

Cipla management outlines new focus areas for the future

Promoter stake sale this year was towards social efforts, management tells shareholders

Mint

Top Gainers and Losers today on 30 August, 2024: Cipla, Bajaj Finance, Tata Motors, Reliance Industries among most active stocks; Check full list here

Top Gainers and Losers Today : The Sensex gained 231.16 points, or 0.28, to settle at 82134.61, while the Nifty gained 83.95 points, or 0.33, to close at 25151.95.

Mint

Stock market today: Trade setup for Nifty 50 to global markets, five stocks to buy or sell on Tuesday

Stocks to buy today: Experts have recommended five shares to buy today — Fiem Industries, Cipla, Deepak Nitrite, JK Lakshmi Cement, and Sterlite Technologies

The Economic Times

F&O stocks to buy today: ONGC, Cipla among top 9 trading ideas for 13 August 2024

The Indian market was poised for consolidation due to mixed global influences. FIIs registered substantial sales while DIIs made significant purchases. Focus was on key index levels and stock picks for short-term trading, including Cipla, Hindustan Unilever, and ONGC, with specific targets and stop-losses provided by experts.

Business Line

Cipla gets ₹773-crore I-T notice

Drugmaker Cipla says it would appeal the order

The Economic Times

Cipla gets Rs 773 crore demand notice from I-T department

The additional demand was raised for disallowances related to deduction of profits and gains derived from the business of developing, maintaining, and operating the infrastructure facilities, expenditure on R&D, business or professional expenses.

Business Standard

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

Orchid Pharma said that it has partnered with Cipla to ensure widespread and rapid distribution of the company's new drug- Cefepime-Enmetazobactam across India.

Business Line

Orchid Pharma ties up with Cipla for new UTI drug’s distribution

It is estimated that the drug sales could reach an annual value of about ₹100 crore, in about 2-3 years

Business Standard

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.

Business Standard

Orchid Pharma join hands with Cipla to launch new antibiotic in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence

Business Line

Mid-day Updates: Sensex rises 100 pts, Nifty 50 at 23,500 level; Adani Ports, Tata Steel, IndusInd, Cipla among top losers

Notably, Kalyani Investment (20%), Vardhman Holdings (20%), JSW Holdings (13.81%), HG Infra (6.34%), and JSW Infra (3.07%) were among the major stocks that hit a 52-week high on the NSE.

Business Line

Stocks that will see action today: June 24, 2024

Buzzing stocks: Car Trade, GRSE, IREDA, Maruti Suzuki, Cipla, Lupin, TVS Motor, JSW Energy, Prestige Estates, Optiemus Infracom, Inox Gree, Capacite Infra, SP Apparels, Arihant Capital, Blue Cloud, Vama Ind

The Economic Times

Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in India

Sun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug, used to treat Gastroesophageal Reflux Disease (GERD) and related acid disorders, will be marketed by Sun Pharma as Voltapraz and by Cipla under their own brands.

The Economic Times

Cipla makes additional investment in German mRNA biotech

Ethris' has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary ciliary dyskinesia - a rare yet chronic respiratory disease. During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.